Duloxetine Capsule, Delayed Release
Product Images NDC 80425-0119

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 80425-0119). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Dr 60mg Cap Qty 30 Ndc 80425 0119

Label for Duloxetine DR 60 mg delayed-release capsules by Advanced Rx Pharmacy of Tennessee, LLC. The label includes the proprietary and generic names, comparison to Cymbalta, NDC 80425-0119-01, lot number, distributor (AJANTA PHARMA L), storage instructions (20°-25°C), and a barcode. The label also contains a caution about federal transfer restrictions.*

FDA Label Image

Duloxetine Dr 60mg Cap Qty 60 Ndc 80425 0119

Label for Duloxetine DR 60 mg delayed-release capsules by Advanced Rx Pharmacy of Tennessee, LLC, Nashville, TN. The label compares the product to Cymbalta and includes NDC 80425-0119-02, source NDC 27214-0099-90, lot and expiration details, manufacturer Ajanta Pharma Ltd, storage instructions, and a barcode.*

FDA Label Image

Image 11

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. The graph illustrates the relationship between pain improvement and patient response for these groups.*

FDA Label Image

Image 2

A Kaplan-Meier survival curve graph showing the proportion of patients with relapse over time from randomization to relapse in days. The graph compares two treatments: Placebo and Duloxetine, indicating relapse rates up to about 200 days.*

FDA Label Image

Image 4

A line graph showing the percentage of patients improved plotted against the percent improvement in pain from baseline. Four groups are compared: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph depicts that higher doses of Duloxetine generally show greater patient improvement in pain compared to placebo across varying levels of percent improvement.*

FDA Label Image

Image 6

A line chart depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved, comparing the three groups over a range of pain improvement levels.*

FDA Label Image

Image 7

A line graph showing percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg taken twice daily, Duloxetine 60 mg once daily, and placebo, illustrating decline in patient improvement percentages as pain improvement thresholds increase.*

FDA Label Image

Image 8

A line graph showing the percentage of patients improved relative to the percent improvement in pain from baseline. Four lines compare Duloxetine at 120 mg once daily, 60 mg once daily, 20 mg once daily, and a placebo. Each line trends downward as percent improvement in pain increases, illustrating patient response to different doses versus placebo.*

FDA Label Image

Image 9

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60/120 mg once daily compared to placebo. The x-axis represents percent improvement in pain (BOCF), and the y-axis shows percentage of patients improved. Duloxetine demonstrates a higher percentage of patients improving across most pain improvement levels compared to placebo.*

FDA Label Image

Image

Chemical structure of Duloxetine, the active ingredient in Duloxetine DR 60 mg delayed-release capsules by Advanced Rx Pharmacy of Tennessee, LLC.*

FDA Label Image

Image10

A line graph comparing the percentage of patients improved between a placebo group and a Duloxetine 60 mg once daily group. The x-axis shows percent improvement in pain from baseline (BOCF), and the y-axis displays the percentage of patients improved. Two lines with markers indicate results for placebo and Duloxetine over a range of pain improvement percentages.*

FDA Label Image

Image3

A line graph comparing the proportion of patients with relapse over time between placebo and duloxetine treatment groups. The x-axis shows time from randomization to relapse in days (0 to 300), and the y-axis shows the proportion of patients with relapse (0.0 to 1.0). The placebo group is represented by a dashed line, showing a higher relapse proportion over time compared to the duloxetine group, represented by a solid line with a lower relapse proportion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.